Indications
Marizev (Omarigliptin) is indicated for the treatment of adults with type 2 diabetes mellitus. It is used to improve blood sugar control in combination with diet and physical activity.
Key Information
Drug Class:
DPP-4 (Dipeptidyl Peptidase-4) Inhibitor.
Dosage Form:
Tablets with a dose of 25 mg (also available in 12.5 mg). Administered once a week orally.
Mechanism of Action:
Omarigliptin inhibits the DPP-4 enzyme, which degrades incretins — hormones that stimulate insulin release and reduce glucose production in the liver. This results in improved blood sugar regulation.
Usage
Dosing Schedule: Taken once weekly, making it convenient and improving treatment adherence.
Combination Therapy: Can be used alone or in combination with other antidiabetic medications.
Side Effects
Upper respiratory tract infections.
Headache.
Nausea.
Allergic reactions (rare).
Risk of hypoglycemia (especially when combined with other glucose-lowering medications).
Contraindications
Hypersensitivity to Omarigliptin or any component of the medication.
Type 1 diabetes mellitus.
Diabetic ketoacidosis.
Important Notes
Medical Supervision: Regular monitoring by a healthcare provider is required before and during treatment.
Storage: Store at room temperature, away from direct sunlight and moisture.
Marizev is an effective and convenient treatment option for type 2 diabetes, offering a simple dosing schedule (once weekly) and minimal side effects, making it a preferred choice for many patients.